China Shineway Pharmaceutical Group Ltd
C1SChina Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products; and research and development of Chinese pharmaceutical products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of BH Corporate Services Ltd. Address: No. 168, Shiluan Street, Shijiazhuang, China, 051430
Analytics
主に工業および宝飾用の金属です。市場が不況を予想し、生産が低下すると、価値は下がります。宝飾品業界からの需要も不安定です。現在、プラチナは金よりも安く、それで作られたアイテムはエリートと見なされません。
104.92 HKD生産が消費をまかなえない場合、供給不足の脅威があります。物理的な金属の不足への恐れの中で、価格は上昇します。しかし、これが不況の予想とともに起こると、価格にはほとんど影響がありません。これは2008年と2023年に明確に見られました。
5.25配当利回り
6.93 %今年
去年
今四半期
前四半期
今年
去年
今四半期
前四半期
主要人物 C1S
配当分析 C1S
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–